Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report - Archive ouverte HAL
Article Dans Une Revue World Journal of Clinical Cases Année : 2021

Dates et versions

hal-03211502 , version 1 (28-04-2021)

Identifiants

Citer

Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière, Xavier Durando. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World Journal of Clinical Cases, 2021, 9 (5), pp.1139-1147. ⟨10.12998/wjcc.v9.i5.1139⟩. ⟨hal-03211502⟩
51 Consultations
0 Téléchargements

Altmetric

Partager

More